MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ijd.70027

Медицинская библиотека · International journal of dermatology · 2025

Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Potestio Luca, Patruno Cataldo, Del Gaudio Marika, Ortoncelli Michela, Ribero Simone, Barei Francesca, Ferrucci Silvia Mariel, Bonzano Laura, Trave Ilaria, Guanti Mario Bruno, Gurioli Carlotta, Piraccini Bianca Maria, Gori Niccolò, Ippoliti Elena, Peris Ketty, Grigolato Laura, Rossi Mariateresa, Foti Caterina, Romita Paolo, Tirone Benedetta, Nettis Eustachio, Esposito Maria, Fargnoli Maria Concetta, Magnanimi Lina Maria, Pezzolo Elena, Hansel Katharina, Stingeni Luca, Satta Rosanna, Mariano Maria, Pigliacelli Flavia, Margiotta Flavia Manzo, Romanelli Marco, Ingurgio Ruggero Cascio, Costanzo Antonio, Narcisi Alessandra, Corazza Monica, Antiga Emiliano, Morrone Pietro, Rubegni Pietro, Calabrese Laura, Lazzeri Laura, Rubegni Giovanni, Guarneri Fabrizio, Zerbinati Nicola, Carugno Andrea, Puca Rosa Valentina, Sarno Oriele, Marasca Claudio, Martina Emanuela, di Vico Francesca, Napolitano Maddalena

СтатьяНаблюдательное исследованиеМногоцентровое исследованиеСравнительное исследованиеПеревод в очереди

Аннотация

BACKGROUND

Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

OBJECTIVE

We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting.

PATIENTS AND

METHODS

A multicenter, retrospective, observational study including adult patients with moderate-to-severe AD treated with dupilumab or tralokinumab for at least 16 weeks was carried out. Demographic, clinical, and therapeutic data were collected from 35 dermatological referral centers across Italy. Conjunctivitis incidence, severity, time to onset, and ophthalmologic management were analyzed and compared between treatment groups.

RESULTS

A total of 6668 patients were included (5899 on dupilumab and 769 on tralokinumab). Conjunctivitis occurred in 10.76% of dupilumab-treated and 12.61% of tralokinumab-treated patients, with no statistically significant difference in overall incidence. However, time to onset was significantly shorter with tralokinumab than with dupilumab (15.3 ± 14.5 weeks vs. 35.5 ± 45.2 weeks, respectively; p < 0.0001). Ophthalmologic management strategies were similar between groups, mainly involving lubricants and corticosteroid-based eye drops. Dupilumab-treated patients more frequently discontinued or switched treatment due to conjunctivitis than tralokinumab patients (25.4% vs. 14.4%, respectively; p < 0.05).

CONCLUSIONS

Conjunctivitis represents a relatively frequent AE in patients with AD receiving dupilumab or tralokinumab. However, earlier onset of conjunctivitis with tralokinumab and higher discontinuation rates with dupilumab suggest differing tolerability profiles. Early recognition of ocular symptoms is essential, and dermatologists should promptly initiate supportive eye care and refer to ophthalmologists when appropriate to avoid unnecessary treatment interruptions.

Для цитирования: Potestio Luca, Patruno Cataldo, Del Gaudio Marika, Ortoncelli Michela, Ribero Simone, Barei Francesca, Ferrucci Silvia Mariel, Bonzano Laura, Trave Ilaria, Guanti Mario Bruno, Gurioli Carlotta, Piraccini Bianca Maria, Gori Niccolò, Ippoliti Elena, Peris Ketty, Grigolato Laura, Rossi Mariateresa, Foti Caterina, Romita Paolo, Tirone Benedetta, Nettis Eustachio, Esposito Maria, Fargnoli Maria Concetta, Magnanimi Lina Maria, Pezzolo Elena, Hansel Katharina, Stingeni Luca, Satta Rosanna, Mariano Maria, Pigliacelli Flavia, Margiotta Flavia Manzo, Romanelli Marco, Ingurgio Ruggero Cascio, Costanzo Antonio, Narcisi Alessandra, Corazza Monica, Antiga Emiliano, Morrone Pietro, Rubegni Pietro, Calabrese Laura, Lazzeri Laura, Rubegni Giovanni, Guarneri Fabrizio, Zerbinati Nicola, Carugno Andrea, Puca Rosa Valentina, Sarno Oriele, Marasca Claudio, Martina Emanuela, di Vico Francesca, Napolitano Maddalena. Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.. International journal of dermatology. 2025. DOI: 10.1111/ijd.70027.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.